Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > January 2013 - Volume 8 - Issue 1 > Current World Literature
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e32835c107d
CURRENT WORLD LITERATURE: Bibliography

Current World Literature

Free Access

This bibliography is compiled by clinicians from the relevant journals scanned by this publication. It is based on the literature regularly pulled into our database from OvidSP (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

▪ Papers considered by the reviewers to be of special interest

▪▪ Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline
15 million on ART by 2015: a realistic target or just a dream
Treatment 2.0: catalyzing the next phase of treatment, care and support

Review: (pp. 4–11)

▪▪. 35Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056. [35]

▪▪. Crawford KW, Ripin DH, Levin AD, et al. participants of The Conference on Antiretroviral Drug O. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more costefficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12:550–560. [15]

▪. Duc Duong Bui FM, Thi Nhan Do, Masaya Kato, et al. Treatment 2.0 Pilot in Vietnam: early progress and challenges. World J AIDS 2012. [39]

▪▪. No Authors Given. WHO. The strategic use of antiretrovirals to help end the HIV epidemic. 2012 www.who.int/hiv/pub/strategic_use. [10]

▪▪. No Authors Given. WHO. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective June 2012. 2012 http://apps.who.int/iris/bitstream/10665/70920/1/9789241503792_eng. pdf. [Accessed 16 July 2012]. [18]

▪. No Authors Given. UNITAID. HIV/AIDS diagnostic technology landscape. 2nd edition 2012; http://www.unitaid.eu/images/marketdynamics/publications/unitaid_md_technical_report_diagnostics_landscape_web.pdf. [23]

▪. No Authors Given. WHO. The Abuja Declaration: Ten Years On. 2011 http://www.who.int/healthsystems/publications/Abuja10.pdf. [Accessed 12 July 2012]. [03]

▪▪. No Authors Given. UNAIDS. Together we will end AIDS. 2012 http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20120718_togetherwewillendaids_en.pdf. [Accessed 29 July 2012]. [06]

▪. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23–31. [27]

▪. Van Rooyen H. High Testing Uptake and Linkages to HIV Treatment through Home-based HIV Counseling and Testing and Facilitated Referral: KwaZulu-Natal, South Africa [abstract]. In: 12th conference on retroviruses and opportunistic infections; Seattle 2012. [24]

Wei CY, Herrick A, Raymond HF, Anglemyer A, et al. Social marketing interventions to increase HIV/STI testing uptake among men who have sex with men and male-to-female transgender women - art. no. CD009337. Cochrane Database Syst Rev 2011 9337.

Back to Top | Article Outline
Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges

Review: (pp. 12–18)

Bertagnolio S, Penazzato M, Jordan MR, Persaud D, et al. World Health Organization Generic Protocol to Assess Drug-Resistant HIV Among Children < 18 Months of Age and Newly Diagnosed With HIV in Resource-Limited Countries. Clin Infect Dis 2012; 54:S254–S260. View Full Text | PubMed | CrossRef

Bertagnolio S, Rodriguez-Diaz RA, Fuentes-Romero LL, Bennett DE, et al. Transmitted HIV Drug Resistance Among Drug-Naive Subjects Recently Infected With HIV in Mexico City: A World Health Organization Survey to Classify Resistance and to Field Test Two Alternative Patient Enrollment Methods. Clin Infect Dis 2012; 54: S328–S333. View Full Text | PubMed | CrossRef

▪▪. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505. [35]

Gorgolas M, Hidalgo C, Williams F, Guerrero MF. Discontinuation Rate of Nevirapine-Based Highly Active Antiretroviral Therapy. Aids Res Hum Retrovir 2012; 28:82. PubMed | CrossRef

▪. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to art care in sub-Saharan Africa: a systematic review. AIDS 2012; 26:2059–2067. [39]

▪. Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS 2012; 26:57–65. [32]

▪▪. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663–1672. [29]

Hogan CM, De Gruttola V, Sun X, Fiscus SA, et al. The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1-Infected Individuals. J Infect Dis 2012; 205:87–96. PubMed | CrossRef

Jarrin I, Pantazis N, Gill MJ, Geskus R, et al. Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clin Infect Dis 2012; 54:111–118. PubMed | CrossRef

Johnson LF, Davies MA, Moultrie H, Sherman GG, et al. The Effect of Early Initiation of Antiretroviral Treatment in Infants on Pediatric AIDS Mortality in South Africa A Model-based Analysis. Pediatr Infect Dis J 2012; 31:474–480. View Full Text | PubMed | CrossRef

Jordan MR, Bennett DE, Wainberg MA, Havlir D, et al. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004–2011. Clin Infect Dis 2012; 54:S245–S249. View Full Text | PubMed | CrossRef

Kelley KF, Caudwell E, Xueref S, Ha TH, et al. Are Countries Using Global Fund Support to Implement HIV Drug Resistance Surveillance? A Review of Funded HIV Grants. Clin Infect Dis 2012; 54:S250–S253. View Full Text | PubMed | CrossRef

Labarga P. New DHHS Guidelines Recommend Antiretroviral Therapy to All HIV-Infected Persons. Aids Rev 2012; 14:154. PubMed

Lazarus R, Struthers H, Violari A. Starting HIV-positive Babies on Antiretroviral Treatment: Perspectives of Mothers in Soweto, South Africa. J Pediatr Health Care 2010; 24:176–183. PubMed | CrossRef

▪▪. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209–216. [25]

Neubert J, Niehues T, Baumann U, Buchholz B, et al. Guideline for Antiretroviral Therapy of HIV-Infected Children and Adolescents. Klinische Padiatr 2012; 224:98–110.

Revell AD, Wang DC, Boyd MA, Emery S, et al. The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. Aids 2011; 25:1855–1863. View Full Text | PubMed | CrossRef

Siberry GK, Harris DR, Oliveira RH, Krauss MR, et al. Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy. Jaids 2012; 60:214–218. View Full Text | PubMed | CrossRef

▪. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23–31. [28]

Vallecillo G, Domingo P, Mallolas J, Blanch J, et al. Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice. Aids Res Hum Retrovir 2012; 28:165–170. PubMed | CrossRef

Zhao Y, Poundstone KE, Montaner J, Wu ZY. New policies and strategies to tackle HIV/AIDS in China. Chin Med J 2012; 125:1331–1337. View Full Text | PubMed

Back to Top | Article Outline
Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa

Review: (pp. 19–26)

Abouyannis M, Menten J, Kiragga A, Lynen L, et al. Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa. Aids 2011; 25:1627–1635. View Full Text | PubMed | CrossRef

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. Aids 2011; 25:2183–2188. View Full Text | PubMed | CrossRef

▪. Aghokeng AF, Kouanfack C, Laurent C, et al. Scale-up of antiretroviral treatment in Cameroon is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011; 25:2183–2188. [15]

Ajoge HO, Gordon ML, Ibrahim S, Shittu OS, et al. Drug Resistance Pattern of HIV Type 1 Isolates Sampled in 2007 from Therapy-Naive Pregnant Women in North-Central Nigeria. Aids Res Hum Retrovir 2012; 28:115–118. PubMed | CrossRef

▪. Ajose O, Mookerjee S, Mills EJ, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929–938. [52]

▪. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410. [56]

Balestre E, Eholie SP, Lokossue A, Sow PS, et al. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids 2012; 26:951–957. View Full Text | PubMed | CrossRef

Bamba S, Lortholary O, Sawadogo A, Millogo A, et al. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. Aids 2012; 26:1039–1041. View Full Text | PubMed | CrossRef

▪. Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345–1354. [50]

▪▪. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 54(Suppl 4) 2012:S280–S289. [30]

▪. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther 2012 [Epub ahead of print]. doi:10.3851/IMP2222. [51]

Campbell JD, Moore D, Degerman R, Kaharuza F, et al. HIV-Infected Ugandan Adults Taking Antiretroviral Therapy With CD4 Counts > 200 Cells/mu L Who Discontinue Cotrimoxazole Prophylaxis Have Increased Risk of Malaria and Diarrhea. Clin Infect Dis 2012; 54:1204–1211. View Full Text | PubMed | CrossRef

Cavalcanti AMS, de Brito AM, Salustiano DM, de Lima KO, et al. Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco. Mem Inst Oswaldo Cruz 2012; 107:450–457. PubMed | CrossRef

Charpentier C, Bellecave P, Cisse M, Mamadou S, et al. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther 2011; 16:429–433. PubMed | CrossRef

Charpentier C, Gody JC, Mbitikon O, Moussa S, et al. Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic. Aids Res Hum Retrovir 2012; 28:87–94. PubMed | CrossRef

Charpentier C, Gody JC, Tisserand P, Matta M, et al. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antivir Ther 2011; 16:1347–1350. PubMed | CrossRef

Dao CN, Peters PJ, Kiarie JN, Zulu I, et al. Hyponatremia, Hypochloremia, and Hypoalbuminemia Predict an Increased Risk of Mortality During the First Year of Antiretroviral Therapy Among HIV-Infected Zambian and Kenyan Women. Aids Res Hum Retrovir 2011; 27: 1149–1155. PubMed | CrossRef

Daoni E, Kitur U, Parunga A, Ndenzako F, et al. Experience in Piloting HIV Drug Resistance Early Warning Indicators to Improve the Antiretroviral Program in Papua New Guinea. Clin Infect Dis 2012; 54:S303–S305. View Full Text | PubMed | CrossRef

Dzangare J, Gonese E, Mugurungi O, Shamu T, et al. Monitoring of Early Warning Indicators for HIV Drug Resistance in Antiretroviral Therapy Clinics in Zimbabwe. Clin Infect Dis 2012; 54:S313–S316. View Full Text | PubMed | CrossRef

Fokam J, Salpini R, Santoro MM, Cento V, et al. Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. Pediatr Infect Dis J 2011; 30:1062–1068. View Full Text | PubMed | CrossRef

Green TN, Archary M, Gordon ML, Padayachi N, et al. Drug Resistance and Coreceptor Usage in HIV Type 1 Subtype C-Infected Children Initiating or Failing Highly Active Antiretroviral Therapy in South Africa. Aids Res Hum Retrovir 2012; 28:324–332. PubMed | CrossRef

▪▪. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250–1258. [16]

▪. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663–1672. [72]

▪. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660–1669. [32]

Hamers RL, Oyomopito R, Kityo C, Phanuphak P, et al. Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43–54. View Full Text | PubMed | CrossRef

▪. Hamers RL, Schuurman R, Sigaloff KC. Effect of pretreatment HIV-1 drug-resistance on immunological, virological and drug-resistance outcomes of first-line antiretroviral treatment: multicentre cohort in six African countries. Lancet Infect Dis 2012; 12:307–317. [21]

Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307–317. PubMed | CrossRef

Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, et al. Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies. Clin Infect Dis 2012; 54:1660–1669. View Full Text | PubMed | CrossRef

Hamers RL, Straatsma E, Kityo C, Wallis CL, et al. Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network. Clin Infect Dis 2012; 54:S261–S265. View Full Text | PubMed | CrossRef

▪▪. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750–759. [14]

Hamers RL, Wallis CL, Kityo C, Siwale M, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750–759. PubMed | CrossRef

Hunt GM, Ledwaba J, Basson AE, Moyes J, et al. Surveillance of Transmitted HIV-1 Drug Resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005–2009. Clin Infect Dis 2012; 54:S334–S338. View Full Text | PubMed | CrossRef

Hunt PW, Cao HL, Muzoora C, Ssewanyana I, et al. Impact of CD8(+) T-cell activation on CD4(+) T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids 2011; 25:2123–2131. View Full Text | PubMed | CrossRef

Hunt PW, Cao HYL, Muzoora C, Ssewanyana I, et al. Impact of CD8(+) T-cell activation on CD4(+) T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids 2011; 25:2123–2131. View Full Text | PubMed | CrossRef

Kambugu A. Pre-ART HIV resistance testing in Africa: are we there yet? Lancet Infect Dis 2012; 12:261.

Koeppe J, Lyda K, Johnson S, Armon C. Variables Associated With Decreasing Pain Among Persons Living With Human Immunodeficiency Virus A Longitudinal Follow-up Study. Clin J Pain 2012; 28:32–38. View Full Text | PubMed | CrossRef

Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 2012; 17:321–326. PubMed | CrossRef

Levison JH, Orrell C, Losina E, Lu ZG, et al. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 2011; 16:853–861. PubMed | CrossRef

▪. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. J Am Med Assoc 2011; 305:1327–1335. [24]

Manasa J, Katzenstein D, Cassol S, Newell ML, et al. Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. Aids Res Hum Retrovir 2012; 28:558–565. PubMed | CrossRef

Mascolini M, Mellors JW, Richman DD, Boucher CAB, et al. HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies. Antivir Ther 2011; 16:263–286. PubMed | CrossRef

Matthews GV, Manzini P, Hu ZH, Khabo P, et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. Aids 2011; 25:1727–1735. View Full Text | PubMed | CrossRef

Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. Aids 2012; 26:497–504. View Full Text | PubMed | CrossRef

▪▪. No Authors Given. WHO. WHO HIV Drug Resistance Report 2012. http://www.who.int/mediacentre/news/notes/2012/hiv_drug_resistance_20120718/en/index.html [Accessed 1 August 2012]. [09]

Ota E, Wariki WMV, Mori R, Hori N, et al. Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in high-income countries - art. no. CD006045. Cochrane Database Syst Rev 2011 6045.

Parczewski M, Leszczyszyn-Pynka M, Urbanska A, Bander D, et al. Genotypic Tropism of Antiretroviral-Treated Patients With Drug Resistant HIV-1. J Med Virol 2011; 83:1869–1875. View Full Text | PubMed | CrossRef

Peterson I, Togun O, de Silva T, Oko F, et al. Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. Aids 2011; 25:2167–2175. View Full Text | PubMed | CrossRef

▪▪. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843–850. [73]

▪. Sigaloff KC, Hamers RL, Wallis CL. Second-line antiretroviral treatment successfully re-suppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis 2012; 205:1739–1744. [49]

▪. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23–31. [04]

Sigaloff KCE, Hamers RL, Wallis CL, Kityo C, et al. Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. Jaids 2011; 58:23–31. View Full Text | PubMed | CrossRef

Sigaloff KCE, Ramatsebe T, Viana R, de Wit TFR, et al. Accumulation of HIV Drug Resistance Mutations in Patients Failing First-Line Antiretroviral Treatment in South Africa. Aids Res Hum Retrovir 2012; 28:171–175. PubMed | CrossRef

Singh A, Sunpath H, Green TN, Padayachi N, et al. Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options. Jaids 2011; 58:233–240. View Full Text | PubMed | CrossRef

Taylor BS, Hunt G, Abrams EJ, Coovadia A, et al. Rapid Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Children Less Than Two Years of Age Initiating Protease Inhibitor-Based Therapy in South Africa. Aids Res Hum Retrovir 2011; 27:945–956. PubMed | CrossRef

▪. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–434. [55]

▪▪. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–422. [57]

van Zyl GU, van der Merwe L, Claassen M, Zeier M, et al. Antiretroviral Resistance Patterns and Factors Associated With Resistance in Adult Patients Failing NNRTI-Based Regimens in the Western Cape, South Africa. J Med Virol 2011; 83:1764–1769. View Full Text | PubMed | CrossRef

▪. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380–2389. [27]

▪. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. The N Engl J Med 2011; 365:637–646. [07]

▪. Wallis CL, Papathanasopoulos M, Fox MP, et al. Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy. Antivir Ther 2012; 17:313–320. [33]

Westergaard RP, Kirk GD, Richesson DR, Galai N, et al. Incarceration Predicts Virologic Failure for HIV-Infected Injection Drug Users Receiving Antiretroviral Therapy. Clin Infect Dis 2011; 53:725–731. View Full Text | PubMed | CrossRef

▪. Westley BP, Delong AK, Tray CS, et al. Prediction of treatment failure using 2010 World Health Organization guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. Clin Infect Dis 2012; 55:432–440. [46]

Back to Top | Article Outline
Transmitted HIV drug resistance in Asia

Review: (pp. 27–33)

Banandur P, Rajaram SP, Mahagaonkar SB, Bradley J, et al. Heterogeneity of the HIV epidemic in the general population of Karnataka state, south India - art. no. S13. BMC Public Health 2011; 11:S13. PubMed | CrossRef

Bhattacharya M, Dubey AP. Adherence to antiretroviral therapy and its correlates among HIV-infected children at an HIV clinic in New Delhi. Ann Trop Paediatr 2011; 31:331–337. PubMed | CrossRef

Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ. Drug Resistance Mutations in HIV Type 1 Isolates from Naive Patients Eligible for First Line Antiretroviral Therapy in JJ Hospital, Mumbai, India. Aids Res Hum Retrovir 2011; 27:1345–1347. PubMed | CrossRef

Duc NB, Hien BT, Wagar N, Tran HT, et al. Surveillance of Transmitted HIV Drug Resistance Using Matched Plasma and Dried Blood Spot Specimens From Voluntary Counseling and Testing Sites in Ho Chi Minh City, Vietnam, 2007–2008. Clin Infect Dis 2012; 54:S343–S347. View Full Text | PubMed | CrossRef

El Annaz H, Recordon-Pinson P, Baba N, Sedrati O, et al. Presence of Drug Resistance Mutations Among Drug-Naive Patients in Morocco. Aids Res Hum Retrovir 2011; 27:917–920. PubMed | CrossRef

▪▪. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250–1258. [02]

Hamers RL, Oyomopito R, Kityo C, Phanuphak P, et al. Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43–54. View Full Text | PubMed | CrossRef

▪. Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis 54(Suppl 4) 2012:S348–S354. [12]

Hingankar NK, Thorat SR, Deshpande A, Rajasekaran S, et al. Initial Virologic Response and HIV Drug Resistance Among HIV-Infected Individuals Initiating First-line Antiretroviral Therapy at 2 Clinics in Chennai and Mumbai, India. Clin Infect Dis 2012; 54:S348–S354. View Full Text | PubMed | CrossRef

Lai CC, Hung CC, Chen MY, Sun HY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012; 67:1254–1260. View Full Text | PubMed | CrossRef

Lee CK, Lee HK, Loh TP, Sethi SK, et al. An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1. J Med Virol 2012; 84:394–401. View Full Text | PubMed | CrossRef

▪. Liao L, Xing H, Dong Y, et al. Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008–2009. Clin Infect Dis 54(Suppl 4) 2012:S320–S323. [13]

Liu J, Chen XM, Xie Q, Zhang WD, et al. Drug Resistance and HCV Coinfection in Former Blood Donors Infected with HIV Type 1 in China. Aids Res Hum Retrovir 2011; 27:925–930. PubMed | CrossRef

▪. Ma Y, Zhang F, Li H, et al. Monitoring HIV drug resistance using early warning indicators in China: results from a pilot survey conducted in 2008. Clin Infect Dis 54(Suppl 4) 2012:S300–S302. [29]

Magee MJ, Blumberg HM, Broz D, Furner SE, et al. Prevalence of drug resistant tuberculosis among patients at high-risk for hiv attending outpatient clinics in delhi, india. Southeast Asian J Trop Med Public Health 2012; 43: 354–363. PubMed

Miri L, Ouladlahsen A, Kettani A, Bensghir R, et al. Characterization of Protease Resistance- Associated Mutations in HIV Type 1 Drug- Naive Patients Following the Increasing Prevalence of the CRF02_AG Strain in Morocco. Aids Res Hum Retrovir 2012; 28:571–577. PubMed | CrossRef

Nguyen HL, Pitakpolrat P, Sirivichayakul S, De laugerre C, et al. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand. J Med Virol 2012; 84:713–720. View Full Text | PubMed | CrossRef

▪▪. No Authors Given. WHO. WHO HIV Drug Resistance Report 2012. http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf [Accessed 13 August 2012]. [05]

Shah S, Xing H, Altaf A, Chen B, et al. Antiretroviral Drug Resistance Mutations Among Treated and Treatment-Naive Patients in Pakistan: Diversity of the HIV Type 1 pol Gene in Pakistan. Aids Res Hum Retrovir 2011; 27:1278–1283. PubMed

Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, et al. Surveillance of Transmitted HIV Type 1 Drug Resistance Among HIV Type 1-Positive Women Attending an Antenatal Clinic in Kakinada, India. Aids Res Hum Retrovir 2011; 27:1292–1298. PubMed

Toor JS, Sharma A, Kumar R, Gupta P, et al. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis. Antiviral Res 2011; 92:213–218. View Full Text | PubMed | CrossRef

▪. Tran VT, Ishizaki A, Nguyen CH, et al. No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in northern Vietnam. AIDS Res Hum Retroviruses 2012; 28:1349–1351. [43]

▪. Wang X, He C, Xing H, et al. Emerging transmitted HIV drug resistance mutations among HIV infected patients prior to start of first-line ART in multiple sites across China. AIDS Res Hum Retroviruses 2012 [Epub ahead of print]. [30]

Ye JR, Lu HY, Wang WS, Guo L, et al. The Prevalence of Drug Resistance Mutations Among Treatment-Naive HIV-Infected Individuals in Beijing, China. Aids Res Hum Retrovir 2012; 28:418–423. PubMed | CrossRef

Zeng PB, Wang JX, Huang Y, Guo XM, et al. The human immunodeficiency virus-1 genotype diversity and drug resistance mutations profile of volunteer blood donors from Chinese blood centers. Transfusion 2012; 52: 1041–1049. View Full Text | PubMed

Zhao B, Han XX, Dai D, Liu J, et al. New Trends of Primary Drug Resistance Among HIV Type 1-Infected Men Who Have Sex with Men in Liaoning Province, China. Aids Res Hum Retrovir 2011; 27:1047–1053. PubMed | CrossRef

Back to Top | Article Outline
Optimizing HIV treatment

Review: (pp. 34–40)

Akanbi MO, Scarci K, Taiwo B, Murphy RL. Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. Expert Opin Pharmacother 2012; 13:65–79. PubMed

Andreoni M, Perno CF. Positioning of HIV-protease inhibitors in clinical practice. Eur Rev Med Pharmacol Sci 2012; 16:10–18. PubMed

Audelin AM, Gerstoft J, Obel N, Mathiesen L, et al. Molecular Phylogenetics of Transmitted Drug Resistance in Newly Diagnosed HIV Type 1 Individuals in Denmark, a Nation-Wide Study. Aids Res Hum Retrovir 2011; 27:1284–1291. PubMed

Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, et al. Recovery From Lipodystrophy in HIV-infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy. Pediatr Infect Dis J 2012; 31: 384–388. View Full Text | PubMed | CrossRef

Baker JV, Neuhaus J, Duprez D, Cooper DA, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. Aids 2011; 25:2133–2142.

Bhatia R, Ryscavage P, Taiwo B. Accelerated aging and human immunodeficiency virus infection: Emerging challenges of growing older in the era of successful antiretroviral therapy. J Neurovirol 2012; 18:247–255. PubMed | CrossRef

Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 2012; 8:11–21. View Full Text | PubMed | CrossRef

Capeau J, Bouteloup V, Katlama C, Bastard JP, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. Aids 2012; 26:303–314. View Full Text | PubMed | CrossRef

Carvalho BC, Cardoso LPV, Damasceno S, Stefani MMD. Moderate Prevalence of Transmitted Drug Resistance and Interiorization of HIV Type 1 Subtype C in the Inland North State of Tocantins, Brazil. Aids Res Hum Retrovir 2011; 27:1081–1087. PubMed | CrossRef

Casotti JAS, Passos LN, de Oliveira FJP, Cerutti C. Prevalence of discordant immunologic and virologic responses in patients with aids under antiretroviral therapy in a specialized care center in brazil. Rev Inst Med Trop Sao Paulo 2011; 53:301–307. PubMed

Castro H, Pillay D, Sabin C, Dunn DT. Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance - art. no. 30. BMC Med Res Methodol 2012; 12:14.

Chandrasekhar A, Gupta A. Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? Am J Clin Nutr 2011; 94:1703S–1715S.

Costagliola D. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012; 12:119–127. PubMed | CrossRef

▪▪. Crawford K, Ripin D, Levin A, et al. Optimising the manufacture, formulation and dose of antiretroviral drugs for more cost-effective delivery in resource-limited settings: a consensus statement. Lancet Infec Dis 2012; 12:550–560. [12]

Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research - art. no. 148. BMC Neurol 2011; 11:22.

da Silva EFR, Fonseca FAH, Franca CN, Ferreira PRA, et al. Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. Aids 2011; 25:1595–1601. View Full Text | PubMed | CrossRef

Daria P, Laura C, Elena R, Davide M, et al. Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? Aids 2011; 25:1430–1433.

De Gascun CF, Waters A, Regan C, O'Halloran J, et al. Documented Prevalence of HIV Type 1 Antiretroviral Transmitted Drug Resistance in Ireland from 2004 to 2008. Aids Res Hum Retrovir 2012; 28:276–281. PubMed | CrossRef

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, et al. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. Antivir Ther 2011; 16:489–497. PubMed | CrossRef

de Mulder M, Yebra G, Martin L, Prieto L, et al. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. J Antimicrob Chemother 2011; 66: 2362–2371. View Full Text | PubMed | CrossRef

Dola CP, Khan R, De Nicola N, Amirgholami M, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2012; 40:51–55. View Full Text | PubMed

Ellis RJ, Badiee J, Vaida F, Letendre S, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. Aids 2011; 25:1747–1751. View Full Text | PubMed | CrossRef

Else LJ, Douglas M, Dickinson L, Back DJ, et al. Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. Antimicrob Agents Chemother 2012; 56:816–824. PubMed | CrossRef

Fourati S, Malet I, Guenzel CA, Soulie C, et al. E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. Antiviral Res 2012; 93:167–174. View Full Text | PubMed | CrossRef

Frange P, Briand N, Avettand-fenoel V, Veber F, et al. Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children Rare Protease Inhibitor Resistance Mutations But High Lamivudine/Emtricitabine Resistance at the Time of Virologic Failure. Pediatr Infect Dis J 2011; 30:684–688. View Full Text | PubMed | CrossRef

Franzetti M, Lai A, Simonetti FR, Bozzi G, et al. High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. J Antimicrob Chemother 2012; 67:1250–1253. View Full Text | PubMed | CrossRef

Galato D, Piovezan AP. Challenges to antiretroviral therapy: can one sentence in medication labelling reduce adherence? Expert Opin Pharmacother 2011; 12:2763–2764.

Garcia F, Alvarez M, Fox Z, Garcia-Diaz A, et al. Predicting antiretroviral drug resistance from the latest or the cumulative genotype. Antivir Ther 2011; 16:373–381. PubMed | CrossRef

Garrido C, Villacian J, Zahonero N, Pattery T, et al. Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. Antimicrob Agents Chemother 2012; 56:2873–2878. PubMed | CrossRef

Gatell JM. Antiretroviral Therapy for HIV: Do Subtypes Matter? Clin Infect Dis 2011; 53:1153–1155.

Gianella S, von Wyl V, Fischer M, Niederoest B, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535–545. PubMed | CrossRef

Gibb DM, Kizito H, Russell EC, Chidziva E, et al. Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial - art. no. e1001217. PLos Med 2012; 9:1217.

Green TC, McGowan SK, Yokell MA, Pouget ER, et al. HIV infection and risk of overdose: a systematic review and meta-analysis. Aids 2012; 26:403–417.

Griffin L, Annaert P, Brouwer KLR. Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of HIV Protease Inhibitors. J Pharm Sci 2011; 100:3636–3654. PubMed

Grijsen ML, Steingrover R, Wit F, Jurriaans S, et al. No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial - art. no. e1001196. PLos Med 2012; 9:1196.

Hanning U, Husstedt IW, Niederstadt TU, Evers S, et al. Cerebral Signal Intensity Abnormalities on T2-weighted MR Images in HIV Patients with Highly Active Antiretroviral Therapy: Relationship with Clinical Parameters and Interval Changes. Acad Radiol 2011; 18:1144–1150. PubMed | CrossRef

Heidari S, Mofenson LM, Hobbs CV, Cotton MF, et al. Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. Jaids 2012; 59:161–169. View Full Text | PubMed | CrossRef

Henderson GJ, Lee SK, Irlbeck DM, Harris J, et al. Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity. Antimicrob Agents Chemother 2012; 56:623–633. PubMed | CrossRef

Hernandez S, Moren C, Lopez M, Coll O, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. Aids 2012; 26:419–428. View Full Text | PubMed | CrossRef

Hester EK. HIV Medications: An Update and Review of Metabolic Complications. Nutr Clin Pract 2012; 27: 51–64. View Full Text | PubMed | CrossRef

Hsieh SM, Chang SY, Hung CC, Sheng WH, et al. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan. Int J STD AIDS 2011; 22:617–620. PubMed | CrossRef

Imaz A, Llibre JM, Ribera E, Clotet B, et al. The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. Jaids 2011; 58:E46–E48. View Full Text | PubMed

Joyce VR, Barnett PG, Chow A, Bayoumi AM, et al. Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV: A Randomized, Controlled Trial. Med Decis Mak 2012; 32:70–82. PubMed | CrossRef

Kalmar EMN, Sanabani SS, da Costa AC, Ferreira S, et al. Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption. Int J STD AIDS 2012; 23:120–125. PubMed | CrossRef

Katende-Kyenda NL, Lubbe MS, Serfontein JHP, Truter I. Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa. Int J STD AIDS 2012; 23:166–172. PubMed | CrossRef

Katsidzira L, Ramsay A, Makunike-Mutasa R, Borok M. Complete regression of early diffuse B-cell lymphoma in an HIV-positive patient on antiretroviral therapy alone. Int J STD AIDS 2011; 22:409–410. PubMed | CrossRef

Kay J, Wanzira H, Sandison T, Kakuru A, et al. Virologic Suppression in Nevirapine-Exposed HIV-Infected Infants Initiating Antiretroviral Therapy in Rural Uganda. J Trop Pediatr 2012; 58:194–199. View Full Text | PubMed | CrossRef

Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, et al. Long-Term Antiretroviral Treatment Outcomes in Seven Countries in the Caribbean. Jaids 2012; 59:E60–E71. View Full Text | PubMed | CrossRef

Konigs C, Feiterna-Sperling C, Esposito S, Viscoli C, et al. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. Aids 2012; 26:447–455. View Full Text | PubMed | CrossRef

Kredo T, Mauff K, Van der Walt JS, Wiesner L, et al. Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients. Antimicrob Agents Chemother 2011; 55:5616–5623. PubMed | CrossRef

Kuniholm MH, Gao XJ, Xue XN, Kovacs A, et al. Human Leukocyte Antigen Genotype and Risk of HIV Disease Progression before and after Initiation of Antiretroviral Therapy. J Virol 2011; 85:10826–10833. PubMed | CrossRef

Lada O, Gervais A, Branger M, Peytavin G, et al. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver Int 2012; 32:93–101.

Lai CC, Hung CC, Chen MY, Sun HY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012; 67:1254–1260. View Full Text | PubMed | CrossRef

Lin D, Seabrook JA, Matsui DM, King SM, et al. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. Pharmacoepidemiol Drug Saf 2011; 20: 1246–1252. View Full Text | PubMed | CrossRef

Llibre JM, Arribas JR, Domingo P, Gatell JM, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. Aids 2011; 25:1683–1690. View Full Text | PubMed | CrossRef

Menendez-Arias L, Betancor G, Matamoros T. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res 2011; 92:139–149. PubMed | CrossRef

Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa. Pediatr Infect Dis J 2011; 30:974–979. View Full Text | PubMed | CrossRef

Morris BL, Scott CA, Wilkin TJ, Sax PE, et al. Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clin Trials 2012; 13:1–10. View Full Text | PubMed | CrossRef

▪▪. No Authors Given. UNAIDS. Together we will end AIDS. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20120718_togetherwewillendaids_en.pdf [Accessed 7 August 2012]. [01]

▪. No Authors Given. Clinton Health Access Initiative (CHAI). Ceiling ARV price list, May 2012. http://www.clintonhealthaccess.org/news-and-information/ARV-Ceiling-Price-List-May-2012 [Accessed 3 August 2012]. [10]

▪. No Authors Given. Medecins sans Frontieres Drug Access Team. Untangling the web of antiretroviral price reductions [July 2012 ed]. http://utw.msfaccess.org/drugs [Accessed 3 August 2012]. [11]

▪. No Authors Given. World Health Organization. Antiretroviral therapy for HIV in adults and adolescents. Recommendations for a public health approach. http://whqlibdoc. who.int/publications/2010/9789241599764_eng.pdf [Accessed 7 August 2012]. [02]

Oliveira V, Bartolo I, Borrego P, Rocha C, et al. Genetic Diversity and Drug Resistance Profiles in HIV Type 1-and HIV Type 2-Infected Patients from Cape Verde Islands. Aids Res Hum Retrovir 2012; 28:510–522. PubMed

Pavie J, Porcher R, Torti C, Medrano J, et al. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66:2372–2378. View Full Text | PubMed | CrossRef

Perez-Molina JA, Diaz-Menendez M, Plana MN, Zamora J, et al. Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials. J Antimicrob Chemother 2012; 67:312–321. View Full Text | PubMed | CrossRef

Pineda JA, Neukam K, Mallolas J, Lopez-Cortes LF, et al. Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. J Infect 2012; 64:204–211. PubMed | CrossRef

Prosperi MCF, Mackie N, Di Giambenedetto S, Zazzi M, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011; 66:1886–1896. View Full Text | PubMed | CrossRef

Rhoads MP, Lanigan J, Smith CJ, Lyall EGH. Effect of Specific ART Drugs on Lipid Changes and the Need for Lipid Management in Children With HIV. Jaids 2011; 57:404–412. View Full Text | PubMed | CrossRef

Roshammar D, Simonsson USH, Ekvall H, Flamholc L, et al. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients. J Pharmacokinet Pharmacodyn 2011; 38:727–742. View Full Text | PubMed | CrossRef

Saphonn V, Saramony S, Vibol U, Sophan S, et al. A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa - art. no. 7. J Int AIDS Soc 2011; 14:9.

Schader SM, Oliveira M, Ibanescu RI, Moisi D, et al. In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine. Antimicrob Agents Chemother 2012; 56:751–756. PubMed | CrossRef

Shapiro RL, Ribaudo H, Powis K, Chen J, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. Aids 2012; 26:120–121. View Full Text | PubMed | CrossRef

Sigaloff KCE, Hamers RL, Wallis CL, Kityo C, et al. Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa. J Infect Dis 2012; 205: 1739–1744. View Full Text | PubMed | CrossRef

Skoura L, Metallidis S, Buckton AJ, Mbisa JL, et al. Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece. J Antimicrob Chemother 2011; 66:2831–2837. View Full Text | PubMed | CrossRef

Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012; 90:128–138. PubMed | CrossRef

Taylor S, Jayasuriya A, Fisher M, Allan S, et al. Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. J Antimicrob Chemother 2012; 67:675–680. View Full Text | PubMed | CrossRef

Torok ME, Farrar JJ. Timing of Antiretroviral Therapy for HIV-1-Associated Tuberculosis REPLY. N Engl J Med 2012; 366:476. View Full Text | PubMed

Torok ME, Farrar JJ. When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis. N Engl J Med 2011; 365:1538–1540. View Full Text | PubMed | CrossRef

Tremeschin MH, Sartorelli DS, Cervi MC, Negrini BVD, et al. Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy. Rev Soc Bras Med Trop 2011; 44:274–281. PubMed | CrossRef

Tsibris AMN, Hu ZX, Paredes R, Leopold KE, et al. Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures. J Virol 2012; 86:6416–6426. PubMed | CrossRef

van Lelyveld SFL, Gras L, Kesselring A, Zhang SJ, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. Aids 2012; 26:465–474. View Full Text | PubMed | CrossRef

Van Rompay KKA. The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. Aids Res Hum Retrovir 2012; 28:16–35. PubMed | CrossRef

Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, et al. European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update. Aids Rev 2011; 13:77–108. PubMed

Wainberg MA, Zaharatos GJ, Brenner BG. MECHANISMS OF DISEASE Development of Antiretroviral Drug Resistance. N Engl J Med 2011; 365:637–646. View Full Text | PubMed | CrossRef

Weber J, Vazquez AC, Winner D, Rose JD, et al. Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 ' Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrob Agents Chemother 2011; 55:3729–3742. PubMed | CrossRef

Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs 2012; 21:395–401. PubMed | CrossRef

Yakasai AM, Muhammad H, Babashani M, Jumare J, et al. Once-daily antiretroviral therapy among treatment-experienced Muslim patients fasting for the month of Ramadan. Trop Dr 2011; 41:233–235.

Yilmaz A, Price RW, Gisslen M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 2012; 67:299–311. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Fifteen million people on antiretroviral treatment by 2015: treatment as prevention

Review: (pp. 41–49)

Alexander CS, Memiah P, Henley YB, Kaiza-Kangalawe A, et al. Palliative Care and Support for Persons with HIV/AIDS in 7 African Countries: Implementation Experience and Future Priorities. Am J Hosp Palliat Med 2012; 29:279–285.

Ambrosioni J, Calmy A, Hirschel B. HIV treatment for prevention - art. no. 28. J Int AIDS Soc 2011; 14:25.

▪▪. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54:714–723. [22]

Baggaley RF, Powers KA, Boily MC. What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Curr Opin HIV AIDS 2011; 6: 131–140.

Boger MS, Bian AH, Shintani A, Milne GL, et al. Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther 2012; 17:485–493. PubMed

▪▪. Clinton HR. Remarks on 'Creating an AIDS-Free Generation'. National Institutes of Health, Masur Auditorium, Bethesda, Maryland, USA; 2011. http://www.state.gov/secretary/rm/2011/11/176810.htm. [01]

▪▪. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505. [24]

Daniels LM, Raasch RH, Corbett AH. Implementation of targeted interventions to decrease antiretroviral-related errors in hospitalized patients. Am J Health-Syst Pharm 2012; 69:422–430. View Full Text | PubMed | CrossRef

Deering KN, Boily MC, Lowndes CM, Shoveller J, et al. A dose-response relationship between exposure to a large-scale HIV preventive intervention and consistent condom use with different sexual partners of female sex workers in southern India - art. no. S8. BMC Public Health 2011; 11:S8. PubMed | CrossRef

▪. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:e1001245. [36]

▪. Granich R, Kahn JG, Bennett R, et al. Expanding ART for Treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS ONE 2012; 7:e30216. [78]

Grossman E, Messerli FH. Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. Am J Med 2012; 125:14–22. PubMed | CrossRef

▪. Gupta S, Granich R, Suthar A, et al. Three I's for HIV/TB and early ART to prevent HIV and TB: policy review of HIV and TB guidelines for high HIV/TB-burden African countries: 19th International AIDS Conference Washington D.C. 2012: Abstract no. WEPDD0205. [41]

▪. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123. [34]

Harries AD, Zachariah R, Chimzizi R, Salaniponi F, et al. Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV - art. no. 593. BMC Public Health 2011; 11:27.

▪. Jones L, Akugizibwe P, Clayton M, et al. Costing human rights and community support interventions as a part of universal access to HIV treatment and care in a Southern African setting. Curr HIV Res 2011; 9:416–428. [80]

Kiser PF, Johnson TJ, Clark JT. State of the Art in Intravaginal Ring Technology for Topical Prophylaxis of HIV Infection. Aids Rev 2012; 14:62–77. PubMed

Lawn SD, Wood R. Timing of Antiretroviral Therapy for HIV-1-Associated Tuberculosis. N Engl J Med 2012; 366:474. View Full Text | PubMed | CrossRef

▪. No Authors Given. PEPFAR. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) seventh annual report to congress. 2011 Washington D.C. http://www.pepfar.gov/press/seventhannualreport/. [13]

▪. No Authors Given. Global Fund against AIDS, Tuberculosis and Malaria. Annual Report, 2011. http://www.theglobalfund.org/en/library/publications/annualreports/. [14]

▪. No Authors Given. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf; Geneva 2011. [15]

▪. No Authors Given. UNAIDS. AIDS at 30: nations at the cross roads. Geneva, Switzerland 2011 http://wwwunaidsorg/unaids_resources/aidsat30/aids-at-30pdf. [03]

▪▪. No Authors Given. Antiretroviral treatment as prevention (TASP) of HIV and TB: Programmatic update. WHO 2012 Geneva http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng. pdf. [39]

▪▪. No Authors Given. UNAIDS. Together we will end AIDS. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20120718_togetherwewillendaids_en.pdf 2012. [04]

▪. No Authors Given. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples. Recommendations for a public health approach http://whqlibdoc.who.int/publications/2012/9789241501972_eng.pdf 2012. [40]

▪. No Authors Given. 2011 Political Declaration on HIV/AIDS. York 2011 http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/06/20110610_UN_A-RES-65-277_en.pdf. [43]

▪▪. No Authors Given. New study finds cost of treating hiv patients is far lower than commonly believed; agreement with generic drug makers will bring prices down even further 2012. Clinton Health Access Initiative, Washington, D.C. (Press Release) http://www.clintonfoundation.org/main/news-and-media/press-releases-and-statements/press-release-agreement-with-generic-drug-makers-will-bring-prices-down-even-further.html. [46]

▪. No Authors Given. UNAIDS. HIV Prevention Revolution. 2010; http://www.hivpreventioncommission.com/index.php?q=node/43. [47]

▪. No Authors Given. UNAIDS. Global AIDS response continues to show results as a record number if people access treatment and rates of new HIV infections fall by nearly 25%. Press release. June 3, 2011. [06]

▪. No Authors Given. WHO. Global Tuberculosis Report 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf. [08]

▪. Resch S, Korenromp E, Stover J, et al. Economic returns to investment in AIDS treatment in low and middle income countries. PLoS ONE 2011; 6:e25310. [79]

Rodger A, Phillips A, Lundgren J. Prevention of HIV-1 Infection with Antiretroviral Therapy. N Engl J Med 2011; 365: 1934. View Full Text | PubMed | CrossRef

▪▪. Schwartlander B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031–2041. [44]

▪▪. Suthar AB, Lawn SD, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9:e1001270. [19]

Tao XH, Shao D, Xue W. Prevention of HIV-1 Infection with Antiretroviral Therapy. N Engl J Med 2011; 365:1934–1935. View Full Text | PubMed | CrossRef

▪▪. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel. JAMA 2012; 308:387–402. [42]

▪▪. Williams BG, Gouws E. Affordability, cost and cost-effectiveness of universal antiretroviral therapy for HIV. arXiv 2012; http://arxiv.org/abs/1206.6774. [45]

Back to Top | Article Outline
The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review

Review: (pp. 50–58)

▪▪. Abdool Karim SS, Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol 2012; 26:427–439. [85]

Alcantara KC, Lins JBA, Albuquerque M, Aires LM, et al. HIV-1 mother-to-child transmission and drug resistance among Brazilian pregnant women with high access to diagnosis and prophylactic measures. J Clin Virol 2012; 54:15–20.

▪. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS 2012. [33]

▪▪. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410. [27]

Cardoso CAA, Pinto JA, Candiani TMS, de Carvalho IR, et al. The impact of highly active antiretroviral therapy on the survival of vertically HIV-infected children and adolescents in Belo Horizonte, Brazil. Mem Inst Oswaldo Cruz 2012; 107:532–538. PubMed | CrossRef

Cartsos VM, Palaska PK, Zavras AI. Antiretroviral Prophylaxis and the Risk of Cleft Lip and Palate: Preliminary Signal Detection in the Food and Drug Administration's Adverse Events Reporting System Database. Cleft Palate-Craniofac J 2012; 49:118–121.

Cohen MS, Chen YQ, Fleming TR. Prevention of HIV-1 Infection with Antiretroviral Therapy REPLY. N Engl J Med 2011; 365:1935. View Full Text | PubMed

▪▪. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505. [62]

Cohen MS, Chen YQ, McCauley M, Gamble T, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; 365:493–505. View Full Text | PubMed | CrossRef

▪. Cohen MS, Muessig KE, Smith MK, et al. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS 2012; 26:1585–1598. [31]

Di Giambenedetto S, Prosperi M, Fanti I, Bruzzone B, et al. Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009. Clin Microbiol Infect 2011; 17:1352–1355. View Full Text | PubMed

Dieffenbach CW. Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda. Curr Opin HIV AIDS 2012; 7:106–110. View Full Text | PubMed

Fernandez-Montero JV, Barreiro P, del Romero J, Soriano V. Antiretroviral Drugs for Pre-Exposure Prophylaxis of HIV Infection. Aids Rev 2012; 14:54–61. PubMed

▪▪. Gengiah TN, Baxter C, Mansoor LE, et al. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 2012; 21:695–715. [10]

Gengiah TN, Baxter C, Mansoor LE, Kharsany ABM, et al. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 2012; 21:695–715. PubMed | CrossRef

▪. Gomez GB, Borquez A, Caceres CF, et al. The potential impact of preexposure prophylaxis for HIV prevention among men who have sex with men in Lima, Peru. PLoS Med 2012 (in press). [53]

▪. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123. [46]

▪. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 Serodiscordant Couples to Use Antiretroviral-Based HIV-1 Prevention Strategies. J Acquir Immune Defic Syndr 2012; 61:116–119. [76]

Hershow RC. Commentary on Thorne, et al. (2012): HIV prevention and treatment in female injection drug users - a work in progress. Addiction 2012; 107:129–130. View Full Text | PubMed | CrossRef

Hurt CB, Eron JJ, Cohen MS. Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 2011; 53:1265–1270.

Kabali C, von Reyn CF, Brooks DR, Waddell R, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis 2011; 15:1515–1521. PubMed | CrossRef

▪. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Preexposure prophylaxis for HIV prevention: how to predict success. Lancet 2012; 379:2409–2411. [32]

Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, Sungkanuparph S, et al. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis 2012; 16:336–341. PubMed | CrossRef

▪▪. Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012; 14:62–77. [88]

Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. Aids 2011; 25:1611–1618.

Muchedzi A, Chandisarewa W, Keatinge J, Stranix-Chibanda L, et al. Factors associated with access to HIV care and treatment in a prevention of mother to child transmission programme in urban Zimbabwe - art. no. 38. J Int AIDS Soc 2010; 13:6.

Mugavero MJ, Amico KR, Westfall AO, Crane HM, et al. Early Retention in HIV Care and Viral Load Suppression: Implications for a Test and Treat Approach to HIV Prevention. Jaids 2012; 59:86–93. View Full Text | PubMed | CrossRef

▪. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent preexposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 2012; 7:e33103. [35]

Namuwenge PM, Mukonzo JK, Kiwanuka N, Wanyenze R, et al. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans Roy Soc Trop Med Hyg 2012; 106:84–89. PubMed | CrossRef

Palombi L, Luhanga R, Galluzzo C, Andreotti M, et al. Limited Risk of Drug Resistance After Discontinuation of Antiretroviral Prophylaxis for the Prevention of Breastfeeding Transmission of HIV. Jaids 2011; 57:301–304. View Full Text | PubMed

Peltzer K, Sikwane E, Majaja M. Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa. Acta Paediatr 2011; 100:1253–1257. View Full Text | PubMed | CrossRef

▪. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science 2011; 333:42–43. [100]

▪▪. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–434. [26]

Thorne C, Semenenko I, Malyuta R. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000–10. Addiction 2012; 107:118–128. View Full Text | PubMed | CrossRef

▪▪. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–422. [29]

▪▪. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preexposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13–F19. [30]

Venkatesh KK, Flanigan TP, Mayer KH. Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. Aids 2011; 25:1939–1949.

Weigel R, Hosseinipour MC, Feldacker C, Gareta D, et al. Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi. Trop Med Int Health 2012; 17:751–759. View Full Text | PubMed | CrossRef

▪. Wheelock A, Eisingerich AB, Gomez GB, et al. Views of policymakers, healthcare workers and NGOs on HIV preexposure prophylaxis (PrEP): a multinational qualitative study. Br Med J Open 2012; 2. [80]

Back to Top | Article Outline
Patching a leaky pipe: the cascade of HIV care

Review: (pp. 59–64)

Ama NO, Seloilwe ES. Estimating the cost of care giving on caregivers for people living with HIV and AIDS in Botswana: a cross-sectional study - art. no. 14. J Int AIDS Soc 2010; 13:20.

Amiya RM, Poudel KC, Poudel-Tandukar K, Kobayashi J, et al. Physicians are a key to encouraging cessation of smoking among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley, Nepal - art. no. 677. BMC Public Health 2011; 11:31.

▪▪. Bärnighausen T, Chaiyachati K, Chimbindi N, et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11:942–951. [44]

Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11:942–951. PubMed | CrossRef

▪. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 54(Suppl 4) 2012:S280–S289. [48]

▪. Bischof JJ, Kuruc JD, Embry JA, et al. Prospective study of the ARCHITECTHIV Ag/Ab Combo fourth generation assay to detect HIV infection in sexually transmitted infection clinics. AIDS 2011; 25:1927–1929. [13]

Brennan AT, Long L, Maskew M, Sanne I, et al. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. Aids 2011; 25:2027–2036. View Full Text | PubMed | CrossRef

▪. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med 2011; 8: e1001102. [09]

▪. Genberg BL, Wilson IB, Bangsberg DR, et al. for the MACH14 Investigators. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS 2012; 26:1415–1423. [31]

Grundmann N, Iliff P, Stringer J, Wilfert C. Presumptive diagnosis of severe HIV infection to determine the need for antiretroviral therapy in children less than 18 months of age. Bull World Health Organ 2011; 89:513–520. PubMed | CrossRef

Hermans SM, van Leth F, Manabe YC, Hoepelman AIM, et al. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. HIV Med 2012; 13:337–344. View Full Text | PubMed | CrossRef

▪▪. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev 2012; 3:CD009756. [37]

Innes C, Hamilton R, Hoffmann CJ, Hippner P, et al. A novel HIV treatment model using private practitioners in South Africa. Sex Transm Infect 2012; 88:136–140. View Full Text | PubMed | CrossRef

Jack N, Ravasi G, Schrooten W, Sutherland D, et al. Implementing Early-Warning Indicators of HIV Drug Resistance in the Caribbean. Clin Infect Dis 2012; 54:S290–S293. View Full Text | PubMed | CrossRef

▪. Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med 2011; 41:83–91. [36]

▪. Kennedy CE, Fonner VA, Sweat MD, et al. Provider-initiated HIV testing and counseling in low- and middle-income countries: a systematic review. AIDS Behav 2012. [08]

Kohler PK, Chung MH, McGrath CJ, Benki-Nugent SF, et al. Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. Aids 2011; 25:1657–1661. View Full Text | PubMed | CrossRef

▪. Kranzer K, van Schaik N, Karmue U, et al. High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa. PLoS One 2011; 6: e25244. [04]

Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11: 825–833. PubMed | CrossRef

Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, et al. Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Individuals. J Am Coll Cardiol 2012; 59:979–988. PubMed | CrossRef

Lopez-Martinez A, Brien NMO, Caro-Vega Y, Crabtree-Ramirez B, et al. Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART Through Clinical Trials Compared With Routine Care in Mexico. Jaids 2012; 59:155–160. View Full Text | PubMed | CrossRef

▪. Ndziessi G, Boyer S, Kouanfack C, et al. Stratall ANRS 12110/ESTHER Study Group. Adherence as a predictor of sexual behaviors in people living with HIV/AIDS during the first year of antiretroviral therapy in rural Cameroon: data from Stratall ANRS 12110/ESTHER trial. PLoS One 2012; 7:e36118. [40]

▪. No Authors Given. Centers for Disease Control and Prevention (CDC). Vital signs: HIV prevention through care and treatment: United States. Morb Mortal Wkly Rep. 2011; 60:1618–1623. [01]

▪. No Authors Given. World Health Organization. Antiretroviral treatment as prevention (TasP) of HIV and TB: 2012 update. Geneva: WHO Press; 2012. [22]

▪▪. No Authors Given. World Health Organization. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva: WHO Press; 2012. [25]

▪▪. No Authors Given. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva: WHO Press, 2011. [03]

▪. No Authors Given. CDC. Compendium of evidence-based HIV behavioral interventions: medication adherence chapter. Updated: July 10, 2012. Accessed: August 25, 2012. http://www.cdc.gov/hiv/topics/research/prs/ma-chapter.htm. [45]

▪▪. No Authors Given. oint United Nations Programme on HIV/AIDS (UNAIDS). Together we will end AIDS. Geneva: UNAIDS; 2012. [26]

Oette M, Schulter E, Rosen-Zvi M, Peres Y, et al. Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort. Intervirology 2012; 55:160–166. PubMed | CrossRef

▪▪. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15:1381–1396. [28]

Pfeiffer J, Montoya P, Baptista AJ, Karagianis M, et al. Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique - a case study - art. no. 3. J Int AIDS Soc 2010; 13:20.

Phelps BR, Hathcock SJ, Werdenberg J, Schutze GE. Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals - art. no. 48. J Int AIDS Soc 2010; 13:6.

Prosperi MCF, Di Giambenedetto S, Fanti I, Meini G, et al. A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen - art. no. 40. BMC Med Inform Decis Mak 2011; 11:14. CrossRef

▪▪. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056. [14]

Schull MJ, Cornick R, Thompson S, Faris G, et al. From PALSA PLUS to PALM PLUS: adapting and developing a South African guideline and training intervention to better integrate HIV/AIDS care with primary care in rural health centers in Malawi - art. no. 82. Implement Sci 2011; 6:26.

Sherer R. The future of HIV care in the USA. Sex Transm Infect 2012; 88:106–111. View Full Text | PubMed | CrossRef

Stein JH. Nutritional Therapy to Prevent Dyslipidemia in Patients Starting Antiretroviral Therapy for Human Immunodeficiency Virus. J Am Coll Cardiol 2012; 59:989– 990. PubMed | CrossRef

▪. Walensky RP, Wood R, Fofana MO, et al. Cost-Effectiveness of Preventing AIDS Complications-International Investigators. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2011; 56:26–35. [02]

Back to Top | Article Outline
HIV and noncommunicable diseases: a case for health system building

Review: (pp. 65–69)

Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, et al. Paradoxical Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Treated With Combination Antiretroviral Therapy After AIDS-Defining Opportunistic Infection. Clin Infect Dis 2012; 54:424–433. View Full Text | PubMed | CrossRef

Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, et al. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant 2011; 26:3224–3229. View Full Text | PubMed | CrossRef

Anglaret X, Minga A, Gabillard D, Ouassa T, et al. AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting Antiretroviral Therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54:714–723. View Full Text | PubMed | CrossRef

Anjos CFD, Schettino GPP, Park M, Souza VS, et al. A Randomized Trial of Noninvasive Positive End Expiratory Pressure in Patients With Acquired Immune Deficiency Syndrome and Hypoxemic Respiratory Failure. Respir Care 2012; 57:211–220. PubMed

Aragones G, Alonso-Villaverde C, Pardo-Reche P, Rull A, et al. Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism - art. no. 120. BMC Med Genet 2011; 12:22.

Asiimwe FM, Moore DM, Were W, Nakityo R, et al. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med 2012; 13:166–171. View Full Text | PubMed

Atashili J, Adimora AA, Ndumbe PM, Ikomey GM, et al. High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? Cancer Epidemiol 2012; 36:263–269.

Boger MS, Bian AH, Shintani A, Milne GL, et al. Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther 2012; 17:485–493. PubMed

Bolland MJ, Grey A, Horne AM, Briggs SE, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol 2012; 76:643–648. View Full Text | PubMed | CrossRef

Boufassa F, Goujard C, Viard JP, Carlier R, et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther 2012; 17:91–100. PubMed | CrossRef

Brewinski M, Megazzini K, Hance LF, Cruz MC, et al. Dyslipidemia in a Cohort of HIV-infected Latin American Children Receiving Highly Active Antiretroviral Therapy*. J Trop Pediatr 2011; 57:324–332. View Full Text | PubMed | CrossRef

Butler SL, Valdez H, Westby M, Perros M, et al. Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy. Jaids 2011; 58:297–303. View Full Text | PubMed | CrossRef

Chang BH, Sommers E. Acupuncture and the relaxation response for treating gastrointestinal symptoms in HIV patients on highly active antiretroviral therapy. Acupunct Med 2011; 29:180–187. View Full Text | PubMed | CrossRef

Coleman SM, Blashill AJ, Gandhi RT, Safren SA, et al. Impact of Integrated and Measurement-Based Depression Care: Clinical Experience in an HIV Clinic. Psychosomatics 2012; 53:51–57. PubMed | CrossRef

Cournil A, Mercier-Deheuvels S, Dupuy AM, Cristol JP, et al. Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire. J Trop Pediatr 2012; 58:43–49. View Full Text | PubMed | CrossRef

Crothers K, Huang L, Butt AA. Risk and Incidence of Pulmonary Diseases among HIV-infected Patients in the Era of Combination Antiretroviral Therapy. Am J Respir Crit Care Med 2011; 184:1087. PubMed | CrossRef

Durval A, Zamidei L, Bettocchi D, Luzzio MG, et al. Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir. Minerva Anestesiol 2011; 77:1018–1021. PubMed

Fabbriciani G, De Socio GVL, Massarotti M. Antiretroviral Therapy and Adverse Skeletal Effects. Mayo Clin Proc 2011; 86:916–917. View Full Text | PubMed | CrossRef

Fisher M, Cooper V. HIV and ageing: premature ageing or premature conclusions? Curr Opin Infect Dis 2012; 25:1–3.

Forrester JE, Rhee MS, McGovern BH, Sterling RK, et al. The association of HIV viral load with indirect markers of liver injury. J Viral Hepatitis 2012; 19:E202–E211. View Full Text | PubMed | CrossRef

Gallego L, Barreiro P, Lopez-Ibor JJ. Psychopharmacological Treatments in HIV Patients under Antiretroviral Therapy. Aids Rev 2012; 14:101–111. PubMed

▪. Grepin KA. Leveraging HIV programs to deliver an integrated package of health services: some words of caution. J Acquir Immune Defic Syndr 57(Suppl 2) 2011:S77–S79. [25]

Guaraldi G, Zona S, Orlando G, Carli F, et al. Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active Antiretroviral Therapy (HAART) Regimens A Cross-Sectional, Observational Study. Clin Drug Invest 2011; 31:759–767. View Full Text | PubMed | CrossRef

Gutierrez F, Masia M. The Role of HIV and Antiretroviral Therapy in Bone Disease. Aids Rev 2011; 13:109–118. PubMed

Hammond E, McKinnon E, Glendenning P, Williams R, et al. Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV. Clin Endocrinol 2012; 76:201–206. View Full Text | PubMed | CrossRef

Hung CC, Chang SY, Lee KY, Sun HY, et al. Risk and Incidence of Pulmonary Diseases among HIV-infected Patients in the Era of Combination Antiretroviral Therapy. Am J Respir Crit Care Med 2011; 184:1086–1087. PubMed | CrossRef

Ingiliz P, Valantin MA, Preziosi P, Finzi L, et al. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis. J Hepatol 2012; 56:49–54. PubMed | CrossRef

Jensen J, Alvaro-Meca A, Micheloud D, Diaz A, et al. Reduction in Mycobacterial Disease Among HIV-infected Children in the Highly Active Antiretroviral Therapy Era (1997–2008). Pediatr Infect Dis J 2012; 31:278–283. View Full Text | PubMed | CrossRef

Kearns AE, Pitts CJD. Antiretroviral Therapy and Adverse Skeletal Effects reply. Mayo Clin Proc 2011; 86:917. View Full Text | PubMed | CrossRef

Kelley KF, Caudwell E, Xueref S, Ha TH, et al. Are Countries Using Global Fund Support to Implement HIV Drug Resistance Surveillance? A Review of Funded HIV Grants. Clin Infect Dis 2012; 54:S250–S253. View Full Text | PubMed | CrossRef

Kim JY, Kim EJ, Choi JY, Kwon OK, et al. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naive patients with HIV/AIDS in Korea. Clin Microbiol Infect 2011; 17:1155–1159. View Full Text | PubMed | CrossRef

Kinyanda E, Hoskins S, Nakku J, Nawaz S, et al. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda - art. no. 205. BMC Psychiatry 2011; 11:30.

Knapp KM, Brogly SB, Muenz DG, Spiegel HML, et al. Prevalence of Congenital Anomalies in Infants With In Utero Exposure to Antiretrovirals. Pediatr Infect Dis J 2012; 31:164–170. View Full Text | PubMed | CrossRef

Krown SE, Roy D, Lee JY, Dezube BJ, et al. Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Study. Jaids 2012; 59:447–454. View Full Text | PubMed | CrossRef

Lanzafame M, Lattuada E, Zoppini G, Vento S. Antiretroviral Therapy-Associated Diseases Are Common in the Long-Term. Aids Res Hum Retrovir 2011; 27:931–932. PubMed | CrossRef

Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 2012; 25:10–16. View Full Text | PubMed | CrossRef

Maggi P, Bartolozzi D, Bonfanti P, Calza L, et al. Renal Complications in HIV Disease: Between Present and Future. Aids Rev 2012; 14:37–53. PubMed

Mansor S, Breiting VB, Dahlstrom K, Andersen AB, et al. Polyacrylamide Gel Treatment of Antiretroviral Therapy-induced Facial Lipoatrophy in HIV Patients. Aesthet Plast Surg 2011; 35:709–716. PubMed | CrossRef

▪▪. Marquez PV, Farrington JL. No more disease silos for sub-Saharan Africa. BMJ 2012; 345:e5812. [07]

Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, et al. The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. Aids Res Hum Retrovir 2011; 27:1300–1310. PubMed

Masia M, Padilla S, Robledano C, Lopez N, et al. Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir. Aids Res Hum Retrovir 2012; 28:242–246. PubMed | CrossRef

Mermis J, Gu HH, Xue B, Li F, et al. Hypoxia-inducible factor-1 alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling - art. no. 103. Respir Res 2011; 12:5. CrossRef

▪. Mills EJ, Ford N. Political lessons from the global HIV/AIDS response to inform a rapid noncommunicable disease response. AIDS 2011; 26:1171–1173. [20]

Morris A, Gingo MR, George MP, Lucht L, et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. Aids 2012; 26:731–740. View Full Text | PubMed | CrossRef

Mosam A, Shaik F, Uldrick TS, Esterhuizen T, et al. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. Jaids 2012; 60:150–157. View Full Text | PubMed | CrossRef

Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 2012; 25:4–9. View Full Text | PubMed | CrossRef

Msango L, Downs JA, Kalluvya SE, Kidenya BR, et al. Renal dysfunction among HIV-infected patients starting antiretroviral therapy. Aids 2011; 25:1421–1425. View Full Text | PubMed

Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. Aids 2012; 26:1073–1082. View Full Text | PubMed | CrossRef

Muronya W, Sanga E, Talama G, Kumwenda JJ, et al. Cardiovascular risk factors in adult Malawians on long-term antiretroviral therapy. Trans Roy Soc Trop Med Hyg 2011; 105:644–649. PubMed | CrossRef

Naito K, Ueno H, Sekine M, Kanemitsu M, et al. Akinetic Mutism Caused by HIV-associated Progressive Multifocal Leukoencephalopathy was Successfully Treated with Mefloquine: A Serial Multimodal MRI Study. Intern Med 2012; 51:205–209. PubMed | CrossRef

Neukam K, Mira JA, Ruiz-Morales J, Rivero A, et al. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother 2011; 66:2605–2614. View Full Text | PubMed | CrossRef

▪▪. Nigatu T. Integration of HIV and noncommunicable diseases in healthcare delivery in low- and middle-income countries. Prev Chronic Dis 2012; 9:E93. [10]

Nishijima T, Tsukada K, Nagata N, Watanabe K, et al. Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome. Aids 2011; 25:1677–1679. View Full Text | PubMed | CrossRef

▪▪. No Authors Given. UNAIDS. Chronic care of HIV and noncommunicable diseases. How to leverage the HIV experience. Geneva: UNAIDS; 2011. [14]

Nurutdinova D, Chrusciel T, Zeringue A, Scherrer JF, et al. Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans. Aids 2012; 26:229–234. PubMed | CrossRef

Overton ET, Patel P, Mondy K, Bush T, et al. Cystatin C and Baseline Renal Function Among HIV-Infected Persons in the SUN Study. Aids Res Hum Retrovir 2012; 28:148–155. PubMed | CrossRef

Pakkala S, Chen ZJ, Rimland D, Owonikoko TK, et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118:164–172. PubMed | CrossRef

▪▪. Rabkin M, El-Sadr WM. Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront noncommunicable diseases. Glob Public Health 2011; 6:247–256. [12]

▪. Rabkin M, Kruk ME, El-Sadr W. HIV, aging and continuity care: strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS 26(Suppl 1) 2012:S77–S83. [05]

▪. Rabkin M, Nishtar S. Scaling up chronic care systems: leveraging HIV programs to support noncommunicable disease services. J Acquir Immune Defic Syndr 57(Suppl 2) 2011:S87–S90. [13]

Ramos MPD, Ferreira SMS, Silva-Boghossian CM, Souto R, et al. Necrotizing periodontal diseases in HIV-infected Brazilian patients: A clinical and microbiologic descriptive study. Quintessence Int 2012; 43:71–82. PubMed

Raynaud C, Roche N, Chouaid C. Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects - art. no. 117. Respir Res 2011; 12:1. CrossRef

Sachdev R, Bansal S, Sinha R, Sharma N, et al. Bilateral Microbial Keratitis in Highly Active Antiretroviral Therapy-induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Case Series. Ocul Immunol Inflamm 2011; 19:343–345. PubMed | CrossRef

Segatto AFM, Freitas IF, dos Santos VR, Alves KCP, et al. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev Soc Bras Med Trop 2011; 44:420–424. PubMed | CrossRef

Senise JF, Castelo A, Martinez M. Current Treatment Strategies, Complications and Considerations for the Use of HIV Antiretroviral Therapy during Pregnancy. Aids Rev 2011; 13:198–213. PubMed

Serrano-Villar S, Estrada V, Gomez-Garre D, Avila M, et al. Incipient Renal Impairment as a Predictor of Subclinical Atherosclerosis in HIV-Infected Patients. Jaids 2012; 59:141–148. View Full Text | PubMed | CrossRef

Sheehan HB, Benetucci J, Muzzio E, Redini L, et al. High rates of serum selenium deficiency among HIV- and HCV-infected and uninfected drug users in Buenos Aires, Argentina. Public Health Nutr 2012; 15:538–545. PubMed | CrossRef

Tamarit MD, Quereda C, Gonzalez-Rozas M, Corral I, et al. HIV Type 1 Viral Encephalitis After Development of Viral Resistance to Plasma Suppressive Antiretroviral Therapy. Aids Res Hum Retrovir 2012; 28:83–86. PubMed | CrossRef

Torti C, Prosperi M, Motta D, Digiambenedetto S, et al. Factors influencing the normalization of CD4+T-cell count, percentage and CD4+/CD8+T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect 2012; 18:449–458. View Full Text | PubMed | CrossRef

Tyerman Z, Aboulafia DM. Review of Screening Guidelines for Non-AIDS-Defining Malignancies: Evolving Issues in the Era of Highly Active Antiretroviral Therapy. Aids Rev 2012; 14:3–16. PubMed

Vannappagari V, Nkhoma ET, Atashili J, St Laurent S, et al. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy. Platelets 2011; 22:611–618. PubMed | CrossRef

▪. Venkat Narayan KM, Ali MK, del Rio C, et al. Global noncommunicable diseases – lessons from the HIV–AIDS experience. N Engl J Med 2011; 365:10. [15]

Wang ZL, Jia RB, Ge SF, He TW, et al. Ocular Complications of Human Immunodeficiency Virus Infection in Eastern China. Am J Ophthalmol 2012; 153:363–369. PubMed | CrossRef

Wu PY, Hung CC, Liu WC, Hsieh CY, et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 2012; 67:1001–1009. View Full Text | PubMed | CrossRef

Wyen C, Jensen B, Hentrich M, Siehl J, et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. Aids 2012; 26:457–464.

Yin Z, Rice BD, Waight P, Miller E, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. Aids 2012; 26:87–94. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
The role of Intellectual Property Rights in treatment access: challenges and solutions

Review: (pp. 70–74)

▪. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med 2012; 9:e1001154. [11]

Car LT, van-Velthoven M, Brusamento S, Elmoniry H, et al. Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries - art. no. CD008741. Cochrane Database Syst Rev 2011 8741.

▪. Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 2011; 14:15. [04]

Back to Top | Article Outline
Introduction 15 million on ART by 2015: a realistic target or just a dream

Elinav H, Pops KO, Shasha D, Korem M, et al. HIV/AIDS profile and realities at a regional antiretroviral therapy clinic in Jerusalem: 12 years analysis. Scand J Infect Dis 2012; 44:65–69. PubMed | CrossRef

Ford N. Commentary: The past, present and future of affordable antiretroviral therapy in Africa. Int J Epidemiol 2012; 41:460–461. View Full Text | PubMed | CrossRef

Nixon SA, Hanass-Hancock J, Whiteside A, Barnett T. The increasing chronicity of HIV in sub-Saharan Africa: Re-thinking ‘‘HIV as a long-wave event’' in the era of widespread access to ART - art. no. 41. Global Health 2011; 7:20.

Reynolds L. HIV as a chronic disease considerations for service planning in resource-poor settings - art. no. 35. Global Health 2011; 7:4.

Skovdal M, Campbell C, Madanhire C, Mupambireyi Z, et al. Masculinity as a barrier to men's use of HIV services in Zimbabwe - art. no. 13. Global Health 2011; 7:15.

Back to Top | Article Outline
Antiretroviral regimen choices

Albrecht M, Mukherjee AL, Tierney C, Morse GD, et al. A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor-Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study. HIV Clin Trials 2011; 12:201–214. View Full Text | PubMed | CrossRef

Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, et al. Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. ChemMedChem 2011; 6:2203–2213. PubMed

Barro M, Some J, Foulongne V, Diasso Y, et al. Short-Term Virological Efficacy, Immune Reconstitution, Tolerance, and Adherence of Once-Daily Dosing of Didanosine, Lamivudine, and Efavirenz in HIV-1-Infected African Children: ANRS 12103 Burkiname. Jaids 2011; 57:S44–S49. View Full Text | PubMed | CrossRef

Berg KM, Litwin AH, Li X, Heo M, et al. Lack of Sustained Improvement in Adherence or Viral Load Following a Directly Observed Antiretroviral Therapy Intervention. Clin Infect Dis 2011; 53:936–943. View Full Text | PubMed | CrossRef

Besson GJ, McMahon D, Maldarelli F, Mellors JW. Short-Course Raltegravir Intensification Does Not Increase 2 Long Terminal Repeat Episomal HIV-1 DNA in Patients on Effective Antiretroviral Therapy. Clin Infect Dis 2012; 54:451–453. View Full Text | PubMed | CrossRef

Briz V, Palladino C, Navarro ML, de Ory SJ, et al. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. HIV Med 2011; 12:442–446. View Full Text | PubMed | CrossRef

Chi BH, Mwango A, Giganti MJ, Sikazwe I, et al. Comparative Outcomes of Tenofovir-Based and Zidovudine-Based Antiretroviral Therapy Regimens in Lusaka, Zambia. Jaids 2011; 58:475–481. View Full Text | PubMed | CrossRef

Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. Aids 2012; 26:253–262. View Full Text | PubMed | CrossRef

Curran A, Martinez E, Saumoy M, del Rio L, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. Aids 2012; 26:475–481. View Full Text | PubMed | CrossRef

del Amo J, Moreno S, Bucher HC, Furrer H, et al. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clin Infect Dis 2012; 54:1364–1372.

Do TN, Nguyen TMT, Do MH, Masaya K, et al. Combining Cohort Analysis and Monitoring of HIV Early-Warning Indicators of Drug Resistance to Assess Antiretroviral Therapy Services in Vietnam. Clin Infect Dis 2012; 54:S306–S312. View Full Text | PubMed | CrossRef

Downey JS, Attaf M, Moyle G, Gazzard B, et al. T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness. Aids 2011; 25:1981–1986. View Full Text | PubMed | CrossRef

Doyle T, Smith C, Vitiello P, Cambiano V, et al. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. Clin Infect Dis 2012; 54:724–732. View Full Text | PubMed | CrossRef

Estrella MM, Kirk GD, Mehta SH, Brown TT, et al. Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. Aids 2012; 26:295–302.

Fenner L, Boulle A, Egger M. Pre-screening with GeneXpert (R) MTB/RIF may increase use of isoniazid preventive therapy in antiretroviral programmes reply. Int J Tuberc Lung Dis 2011; 15:1273–1274. PubMed | CrossRef

Gatell JM. Antiretroviral Therapy for HIV: Do Subtypes Matter? Clin Infect Dis 2011; 53:1153–1155.

Goetghebuer T, Le Chenadec J, Haelterman E, Galli L, et al. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clin Infect Dis 2012; 54:878–881. View Full Text | PubMed | CrossRef

Hazra R, Cohen RA, Gonin R, Monteiro JP, et al. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. Aids 2012; 26:235–240. PubMed | CrossRef

Heijman T, Geskus RB, Davidovich U, Coutinho RA, et al. Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era. Aids 2012; 26:489–495. View Full Text | PubMed | CrossRef

Huntington SE, Bansi LK, Thorne C, Anderson J, et al. Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Aids 2011; 25:1647–1655. View Full Text | PubMed | CrossRef

Imaz A, Falco V, Ribera E. Antiretroviral Salvage Therapy for Multiclass Drug-Resistant HIV-1-Infected Patients: From Clinical Trials to Daily Clinical Practice. Aids Rev 2011; 13:180–193. PubMed

Judd A, Penazzato M, Townsend C, Duong T, et al. Early antiretroviral therapy in HIV-1-infected infants, 1996–2008: treatment response and duration of first-line regimens. Aids 2011; 25:2279–2287. View Full Text | PubMed

Kiser PF, Johnson TJ, Clark JT. State of the Art in Intravaginal Ring Technology for Topical Prophylaxis of HIV Infection. Aids Rev 2012; 14:62–77. PubMed

Kiwuwa-Muyingo S, Walker AS, Oja H, Levin J, et al. The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Trop Med Int Health 2012; 17:584–594. View Full Text | PubMed | CrossRef

Labarga P. When to Start Antiretroviral Therapy in HIV Patients with Tuberculosis. Aids Rev 2012; 14:78–79. PubMed

Levy Y, Thiebaut R, Gougeon ML, Molina JM, et al. Effect of intermittent interleukin-2 therapy on CD4(+) T-cell counts following antiretroviral cessation in patients with HIV. Aids 2012; 26:711–720. View Full Text | PubMed | CrossRef

Mosam A, Shaik F, Uldrick TS, Esterhuizen T, et al. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. Jaids 2012; 60:150–157. View Full Text | PubMed | CrossRef

Mtambo A, Chan K, Shen A, Lima V, et al. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. HIV Med 2012; 13:141–147. View Full Text | PubMed

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, et al. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study. Jaids 2011; 58:253–260.

Nishijima T, Tsukada K, Takeuchi S, Chiba A, et al. Antiretroviral Therapy for Treatment-naive Chronic HIV-1 Infection with an Axonal Variant of Guillain-Barre Syndrome Positive for Anti-ganglioside Antibody: A Case Report. Intern Med 2011; 50:2427–2429. PubMed | CrossRef

Ouattara EN, Anglaret X, Wong AY, Chu J, et al. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. Aids 2012; 26:625–634. View Full Text | PubMed | CrossRef

Robertson J, Feinberg J. Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opin Pharmacother 2012; 13:1363–1375. PubMed | CrossRef

Smith RA, Raugi DN, Kiviat NB, Hawes SE, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. Aids 2011; 25:2235–2241. View Full Text | PubMed | CrossRef

Vallecillo G, Domingo P, Mallolas J, Blanch J, et al. Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice. Aids Res Hum Retrovir 2012; 28:165–170. PubMed | CrossRef

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111–118. PubMed | CrossRef

Van Rompay KKA. The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. Aids Res Hum Retrovir 2012; 28:16–35. PubMed | CrossRef

Vitiello P, Brudney D, MacCartney M, Garcia A, et al. Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load. Intervirology 2012; 55:172–178. PubMed | CrossRef

Vrouenraets SME, Wit F, Garcia EF, Huber M, et al. Longer Prior Exposure to Zidovudine/Lamivudine-Containing Combination Antiretroviral Therapy, Age, and Male Gender Are Each Associated With Reduced Subcutaneous Adipose Tissue. HIV Clin Trials 2012; 13:103–110. View Full Text | PubMed | CrossRef

Zhang H, Qin F, Ye W, Li Z, et al. Revealing the Drug-Resistant Mechanism for Diarylpyrimidine Analogue Inhibitors of HIV-1 Reverse Transcriptase. Chem Biol Drug Des 2011; 78:427–437. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Resource needs for universal antiretroviral treatment access

Ajose O, Mookerjee S, Mills EJ, Boulle A, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Aids 2012; 26:929–938. View Full Text | PubMed | CrossRef

Argemi X, Dara S, You S, Mattei JF, et al. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. Aids 2012; 26:1161–1166. View Full Text | PubMed | CrossRef

Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther 2011; 16:895–903. PubMed | CrossRef

Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, et al. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions - art. no. 59. BMC Med 2011; 9:20.

Eley BS, Meyers T. Antiretroviral Therapy for Children in Resource-Limited Settings Current Regimens and the Role of Newer Agents. Pediatr Drugs 2011; 13:303–316.

Gormley W, McCaffery J, Quain EE. Moving Forward on Human Resources for Health: Next Steps for Scaling Up Toward Universal Access to HIV/AIDS Prevention, Treatment, and Care. Jaids 2011; 57:S113–S115. View Full Text | PubMed | CrossRef

Koenig SP, Bang H, Severe P, Juste MAJ, et al. Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti - art. no. e1001095. PLos Med 2011; 8:1095.

Long L, Brennan A, Fox MP, Ndibongo B, et al. Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ART Patients to Nurses in South Africa: An Observational Cohort - art. no. e1001055. PLos Med 2011; 8:1055.

Montague BT, Vuylsteke B, Buve A. Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention - art. no. 701. BMC Public Health 2011; 11:14.

Mosoko JJ, Akam W, Weidle PJ, Brooks JT, et al. Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon - art. no. 32. J Int AIDS Soc 2011; 14:16.

Murray M, Hogg RS, Lima VD, May MT, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2012; 13:89–97. View Full Text | PubMed | CrossRef

Reynolds L. HIV as a chronic disease considerations for service planning in resource-poor settings - art. no. 35. Global Health 2011; 7:4.

Schmidt NC, Roman-Pouriet J, Fernandez AD, Beck-Sague CM, et al. Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. Int J Gynecol Obstet 2012; 116:219–222. PubMed | CrossRef

Sigaloff KCE, Calis JCJ, Geelen SP, van Vugt M, et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011; 11:769–779. PubMed | CrossRef

Than NN, Sungkanuparph S, Maek ANW, Kaewkungwal J, et al. Comparison of clinical outcomes between hiv-infected patients with and without hcv co-infection in a resource-limited setting. Southeast Asian J Trop Med Public Health 2012; 43:646–651. PubMed

Torpey K, Mwenda L, Thompson C, Wamuwi E, et al. From project aid to sustainable HIV services: a case study from Zambia - art. no. 19. J Int AIDS Soc 2010; 13:7.

Wei CY, Herrick A, Raymond HF, Anglemyer A, et al. Social marketing interventions to increase HIV/STI testing uptake among men who have sex with men and male-to-female transgender women - art. no. CD009337. Cochrane Database Syst Rev 2011 9337.

Weiser SD, Tsai AC, Gupta R, Frongillo EA, et al. Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. Aids 2012; 26:67–75. View Full Text | PubMed | CrossRef

Wester CW, Koethe JR, Shepherd BE, Stinnette SE, et al. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. Aids 2011; 25:1471–1479. View Full Text | PubMed | CrossRef

Zeng W, Shepard DS, Chilingerian J, Avila-Figueroa C. How much can we gain from improved efficiency? An examination of performance of national HIV/AIDS programs and its determinants in low- and middle-income countries - art. no. 74. BMC Health Serv Res 2012; 12:24.

Back to Top | Article Outline
Real life obstacles to scaling up ART

Armstrong G, Humtsoe C, Kermode M. HIV risk behaviours among injecting drug users in Northeast India following scale-up of a targeted HIV prevention programme - art. no. S9. BMC Public Health 2011; 11:S9. PubMed | CrossRef

Bedimo R, Maalouf NM, Zhang S, Drechsler H, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Aids 2012; 26:825–831. View Full Text | PubMed | CrossRef

Boyer S, Koulla-Shiro S, Abe C, Spire B, et al. Implementing operational research to scale-up access to antiretroviral therapy for HIV infection: lessons learned from the Cameroonian experience. Curr Opin HIV AIDS 2011; 6:239–244. View Full Text | PubMed

Cameron D. Scale-Up And Continuation of Antiretroviral Therapy in South African Treatment Programs, 2005–2009. Jaids 2011; 57:E92. View Full Text | PubMed | CrossRef

Charpentier C, Larrouy L, Matheron S, Damond F, et al. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther 2011; 16:937–940. PubMed | CrossRef

Chege D, Kovacs C, la Porte C, Ostrowski M, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. Aids 2012; 26:167–174. PubMed | CrossRef

Dray-Spira R, Legeai C, Le Den M, Boue F, et al. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. Aids 2012; 26:207–215. PubMed | CrossRef

Evans D, Maskew M, Sanne I. Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113:362–372. PubMed | CrossRef

Fox ZV, Cozzi-Lepri A, Monforte AD, Karlsson A, et al. Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antivir Ther 2011; 16:781–785. PubMed | CrossRef

Frentz D, Boucher CAB, van de Vijver D. Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World. Aids Rev 2012; 14:17–27. PubMed

Grierson J, Koelmeyer RL, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med 2011; 12:562–569. View Full Text | PubMed | CrossRef

Groh K, Audet CM, Baptista A, Sidat M, et al. Barriers to antiretroviral therapy adherence in rural Mozambique - art. no. 650. BMC Public Health 2011; 11:16.

Gsponer T, Petersen M, Egger M, Phiri S, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. Aids 2012; 26:57–65. View Full Text | PubMed | CrossRef

Haubrich RH, Riddler SA, Ribaudo H, Di Renzo G, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. Aids 2011; 25: 2269–2278.

Hearps AC, Maisa A, Cheng WJ, Angelovich TA, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. Aids 2012; 26:843–853. View Full Text | PubMed | CrossRef

Hunt GM, Coovadia A, Abrams EJ, Sherman G, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. Aids 2011; 25:1461–1469. View Full Text | PubMed | CrossRef

Hurt CB, Eron JJ, Cohen MS. Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 2011; 53:1265–1270.

Kowalska JD, Reekie J, Mocroft A, Reiss P, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. Aids 2012; 26:315–323. View Full Text | PubMed | CrossRef

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. Aids 2012; 26:185–192. PubMed | CrossRef

McMahon JH, Wanke CA, Elliott JH, Skinner S, et al. Repeated Assessments of Food Security Predict CD4 Change in the Setting of Antiretroviral Therapy. Jaids 2011; 58:60–63.

Milloy MJ, Kerr T, Buxton J, Rhodes T, et al. Social and Environmental Predictors of Plasma HIV RNA Rebound Among Injection Drug Users Treated With Antiretroviral Therapy. Jaids 2012; 59:393–399. View Full Text | PubMed | CrossRef

Montague BT, Vuylsteke B, Buve A. Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention - art. no. 701. BMC Public Health 2011; 11:14.

Nie T, Detorio M, Schinazi RF. Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes. Antivir Ther 2011; 16:1267–1275. PubMed | CrossRef

Preidis GA, McCollum ED, Mwansambo C, Kazembe PN, et al. Pneumonia and Malnutrition are Highly Predictive of Mortality among African Children Hospitalized with Human Immunodeficiency Virus Infection or Exposure in the Era of Antiretroviral Therapy. J Pediatr 2011; 159: 484–489. View Full Text | PubMed | CrossRef

Sloan CE, Champenois K, Choisy P, Losina E, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. Aids 2012; 26:45–56. View Full Text | PubMed | CrossRef

Taniguchi T, Nurutdinova D, Grubb JR, Onen NF, et al. Transmitted Drug-Resistant HIV Type 1 Remains Prevalent and Impacts Virologic Outcomes Despite Genotype-Guided Antiretroviral Therapy. Aids Res Hum Retrovir 2012; 28:259–264. PubMed | CrossRef

Weigel R, Estill J, Egger M, Harries AD, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. Aids 2012; 26:365–373. View Full Text | PubMed | CrossRef

Westin MR, Biscione FM, Fonseca M, Ordones M, et al. Resistance-Associated Mutation Prevalence According to Subtypes B and Non-B of HIV Type 1 in Antiretroviral-Experienced Patients in Minas Gerais, Brazil. Aids Res Hum Retrovir 2011; 27:981–987. PubMed | CrossRef

Back to Top | Article Outline
Innovative financing mechanisms for HIV prevention and care: PEPFAR, CHAI, UNAIDS

Avdeeva O, Lazarus JV, Aziz MA, Atun R. The Global Fund's resource allocation decisions for HIV programmes: addressing those in need - art. no. 51. J Int AIDS Soc 2011; 14:26.

Larson E, O'Bra H, Brown JW, Mbengashe T, et al. Supporting the massive scale-up of antiretroviral therapy: the evolution of PEPFAR-supported treatment facilities in South Africa, 2005–2009 - art. no. 173. BMC Public Health 2012; 12:9.

Leelahavarong P, Teerawattananon Y, Werayingyong P, Akaleephan C, et al. Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand - art. no. 534. BMC Public Health 2011; 11:5.

Leibowitz AA, Mendes AC, Desmond K. Public Funding of HIV/AIDS Prevention, Treatment, and Support in California. Jaids 2011; 58:E11–E16. View Full Text | PubMed | CrossRef

Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. Aids 2012; 26:1083–1093. View Full Text | PubMed | CrossRef

Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. Aids 2012; 26:355–364. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Conclusion: where to go from here

Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research - art. no. 148. BMC Neurol 2011; 11:22.

Ford N. Commentary: The past, present and future of affordable antiretroviral therapy in Africa. Int J Epidemiol 2012; 41:460–461. View Full Text | PubMed | CrossRef

Maggi P, Bartolozzi D, Bonfanti P, Calza L, et al. Renal Complications in HIV Disease: Between Present and Future. Aids Rev 2012; 14:37–53. PubMed

Yoder RB, Nyandiko WM, Vreeman RC, Ayaya SO, et al. Long-Term Impact of the Kenya Postelection Crisis on Clinic Attendance and Medication Adherence for HIV-Infected Children in Western Kenya. Jaids 2012; 59:199–206. View Full Text | PubMed | CrossRef

Zhao Y, Poundstone KE, Montaner J, Wu ZY. New policies and strategies to tackle HIV/AIDS in China. Chin Med J 2012; 125:1331–1337. View Full Text | PubMed

Back to Top | Article Outline
Miscellaneous

. Abstracts presented at the International Workshop on HIV Et Hepatitis Virus Drug Resistance and Curative Strategies June 7–11 2011, Los Cabos, Mexico Abstracts. Antivir Ther 2011; 16:A3. PubMed

Aragones-Lopez C, Perez-Avila J, Fawzi MCS, Castro A. Quality of Life of People With HIV/AIDS Receiving Antiretroviral Therapy in Cuba: A Cross-Sectional Study of the National Population. Am J Public Health 2012; 102:884–892. View Full Text | PubMed | CrossRef

Barth RE, Aitken SC, Tempelman H, Geelen SP, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012; 17:377–386. PubMed | CrossRef

Beachler DC, Weber KM, Margolick JB, Strickler HD, et al. Risk Factors for Oral HPV Infection among a High Prevalence Population of HIV-Positive and At-Risk HIV-Negative Adults. Cancer Epidemiol Biomarkers Prev 2012; 21:122–133. PubMed | CrossRef

Bennett DE, Jordan MR, Bertagnolio S, Hong SY, et al. HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries. Clin Infect Dis 2012; 54:S280–S289. View Full Text | PubMed | CrossRef

Chang MW, Torbett BE. Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 Protease. J Mol Biol 2011; 410:756–760. PubMed | CrossRef

Cozzi-Lepri A, Paredes R, Phillips AN, Clotet B, et al. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med 2012; 13:62–72. View Full Text | PubMed

de Felipe B, Perez-Romero P, Abad-Fernandez M, Fernandez-Cuenca F, et al. Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000–2010 - art. no. 416. Virol J 2011; 8:26.

de Medeiros RM, Junqueira DM, Matte MCC, Barcellos NT, et al. Co-Circulation HIV-1 Subtypes B, C, and CRF31_BC in a Drug-Naive Population From Southernmost Brazil: Analysis of Primary Resistance Mutations. J Med Virol 2011; 83:1682–1688. View Full Text | PubMed | CrossRef

Dvali N, Parker MM, Chkhartishvili N, Sharvadze L, et al. Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. J Med Virol 2012; 84:1002–1008. View Full Text | PubMed | CrossRef

Gandhi RT, Deeks SG. Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough? Clin Infect Dis 2012; 54:733–735.

Garcia F, Perez-Cachafeiro S, Guillot V, Alvarez M, et al. Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS). Antiviral Res 2011; 91:150–153. View Full Text | PubMed | CrossRef

Goethals O, Van Ginderen M, Vos A, Cummings MD, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res 2011; 91:167–176. View Full Text | PubMed | CrossRef

Gompels UA, Larke N, Sanz-Ramos M, Bates M, et al. Human Cytomegalovirus Infant Infection Adversely Affects Growth and Development in Maternally HIV-Exposed and Unexposed Infants in Zambia. Clin Infect Dis 2012; 54:434–442. View Full Text | PubMed | CrossRef

McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, et al. Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines. Antimicrob Agents Chemother 2012; 56:3232–3238. PubMed | CrossRef

Muwonga J, Edidi S, Butel C, Vidal N, et al. Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. Jaids 2011; 57:S27–S33. View Full Text | PubMed | CrossRef

Oette M, Reuter S, Kaiser R, Lengauer T, et al. Epidemiology of Transmitted Drug Resistance in Chronically HIV-Infected Patients in Germany: The RESINA Study 2001–2009. Intervirology 2012; 55:154–159. PubMed | CrossRef

Parham L, de Rivera IL, Murillo W, Naver L, et al. Short Communication: High Prevalence of Drug Resistance in HIV Type 1-Infected Children Born in Honduras and Belize 2001 to 2004. Aids Res Hum Retrovir 2011; 27:1055–1059. PubMed | CrossRef

Prosperi MCF, De Luca A. Computational Models for Prediction of Response to Antiretroviral Therapies. Aids Rev 2012; 14:145–153. PubMed

Pulido F, Hill A, van Delft Y, Moecklinghoff C. Impact of Hepatitis C Co-Infection on Response to Antiretroviral Treatment. Aids Rev 2012; 14:124–131. PubMed

Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase - art. no. 34. BMC Med 2012; 10:12.

Romero A, Sued O, Puig T, Esteve A, et al. Prevalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1 Subtypes Among Patients with Recent Infection in Catalonia (Spain) between 2003 and 2005. Enferm Infec Microbiol Clin 2011; 29:482–489. PubMed | CrossRef

Sabapathy K, Ford N, Chan KN, Kyaw MK, et al. Treatment Outcomes From the Largest Antiretroviral Treatment Program in Myanmar (Burma): A Cohort Analysis of Retention After Scale-Up. Jaids 2012; 60:E53–E62. View Full Text | PubMed | CrossRef

Soria J, Bull M, Mitchell C, La Rosa A, et al. Transmitted HIV Resistance to First-Line Antiretroviral Therapy in Lima, Peru. Aids Res Hum Retrovir 2012; 28:333–338. PubMed | CrossRef

Staehelin C, Keiser O, Calmy A, Weber R, et al. Longer Term Clinical and Virological Outcome of Sub-Saharan African Participants on Antiretroviral Treatment in the Swiss HIV Cohort Study. Jaids 2012; 59:79–85. View Full Text | PubMed | CrossRef

Sturmer M, Stephan C, Gute P, Knecht G, et al. Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naive Patients Infected with HIV-1 B and Non-B Subtypes. Antimicrob Agents Chemother 2011; 55:5362–5366. PubMed | CrossRef

Sungkanuparph S, Kiertiburanakul S, Sukasem C, Chantratita W. Discrepancies Between WHO 2009 and IAS-USA 2009 Lists for Determining the Rate of Transmitted HIV-1 Drug Resistance: A Prospective Study. Jaids 2012; 59:E3–E5. View Full Text | PubMed | CrossRef

Tho DQ, Torok ME, Nguyen TBY, Bang ND, et al. Influence of Antituberculosis Drug Resistance and Mycobacterium tuberculosis Lineage on Outcome in HIV-Associated Tuberculous Meningitis. Antimicrob Agents Chemother 2012; 56:3074–3079. PubMed | CrossRef

Victoriano AFB, Okamoto T. Transcriptional Control of HIV Replication by Multiple Modulators and Their Implication for a Novel Antiviral Therapy. Aids Res Hum Retrovir 2012; 28:125–138. PubMed | CrossRef

Waheed AA, Freed EO. HIV Type 1 Gag as a Target for Antiviral Therapy. Aids Res Hum Retrovir 2012; 28:54–75. PubMed | CrossRef

Waters L, Smit E. HIV-1 superinfection. Curr Opin Infect Dis 2012; 25:42–50. View Full Text | PubMed | CrossRef

© 2013 Lippincott Williams & Wilkins, Inc.

Login